Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

Objective Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation. Co-administration with CYP inhibitors may inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pithavala, Yazdi K., Tong, Warren, Mount, Janessa, Rahavendran, Sadayappan V., Garrett, May, Hee, Brian, Selaru, Paulina, Sarapa, Nenad, Klamerus, Karen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256319/
https://www.ncbi.nlm.nih.gov/pubmed/20740300
http://dx.doi.org/10.1007/s10637-010-9511-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256319/
https://www.ncbi.nlm.nih.gov/pubmed/20740300
http://dx.doi.org/10.1007/s10637-010-9511-6

Ejemplares similares